Ademex Study Expands Patient Pool
PD is a robust therapy - 2 year survival rates were comparable to HD
Patients can stay on PD longer, reducing drop-off
Patients currently excluded from PD option (e.g. body size, transport status) may benefit
Patient survival rates were the same throughout 33 months of treatment and follow-up